NCT00250094View on ClinicalTrials.gov

Clinical Benefit of Topoisomerase Downregulation

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

June 30, 2005

Study Completion Date

March 31, 2006

Conditions
Ovarian Cancer
Interventions
DRUG

Topotecan and VP16

"Course 1A: On day 1 treatment will start with a continuous infusion of TPT at 0.4 mg/m2/day for 21 days. A pump will be used to deliver the TPT. The bag in the pump will be replaced every week for sterility precautions.~Course 1B: On day 28, if ANC is \>1,500 and platelets \> 100,000, VP-16 will be administered orally at 50 mg/day for 14 days."

Trial Locations (1)

87131

University of New Mexico, Albuquerque

All Listed Sponsors
lead

New Mexico Cancer Research Alliance

OTHER

NCT00250094 - Clinical Benefit of Topoisomerase Downregulation | Biotech Hunter | Biotech Hunter